Nicotinamide Mononucleotide in Patients Undergoing CABG Surgery

Recruiting Phase 2 Interventional Study
Coronary Artery Bypass Graft
Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Trial phase
Phase 2
Study type
Interventional
Purpose
Treatment
Participants needed
90 (estimated)
Sponsor
Brigham and Women's Hospital · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

The investigators will perform a phase 2a, randomized, double-blind, placebo-controlled clinical trial in adult patients undergoing elective coronary artery bypass grafting (CABG) surgery to investigate the effects of oral nicotinamide mononucleotide (NMN) administration on myocardial NAD+ concentrations and on postoperative markers of myocardial and kidney injury.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: 1. Age ≥18 years 2. Scheduled to undergo elective isolated CABG surgery with cardiopulmonary bypass (CPB) 3. At increased risk of postoperative complications based on ≥1 of the following: 1. Age ≥65 years 2. eGFR \<45 ml/min/1.73m2 3. Documented history of congestive h…
Contacts

Shalender Bhasin, MB,BS

617-525-9150

sbhasin@bwh.harvard.edu

CONTACT

David E Leaf, MD

617-732-5951

deleaf@bwh.harvard.edu

CONTACT